Tibsovo Global Market Report 2026

Tibsovo is an oral targeted therapy mainly prescribed for adults with acute myeloid leukemia (AML) or cholangiocarcinoma who carry a specific mutation in the IDH1 gene. It works by inhibiting the mutated IDH1 enzyme, thereby lowering the levels of an abnormal metabolite that drives cancer cell growth. This action helps restore normal cell differentiation and slows disease progression.

The main product types of Tibsovo include tablets, capsules, combination therapy, and injectable forms. Tablets represent the oral solid dosage form of ivosidenib and are designed for convenient once-daily use. These products are administered via oral and intravenous routes and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in applications such as cancer treatment, acute myeloid leukemia management, chemotherapy, and targeted therapy, serving end users including hospitals, specialty clinics, research institutions, and homecare settings.

Tariffs have affected the tibsovo market by increasing costs of imported raw materials and active pharmaceutical ingredients (apis) required for oral targeted therapies. Segments such as tablets, capsules, and combination therapy products are particularly impacted, with regions like North America and Europe facing supply chain adjustments due to import duties. While tariffs may increase drug prices and production costs, they also encourage domestic manufacturing, innovation in apis, and localization of supply chains, ultimately strengthening regional production capabilities.

The tibsovo market research report is one of a series of new reports from The Business Research Company that provides tibsovo market statistics, including tibsovo industry global market size, regional shares, competitors with a tibsovo market share, detailed tibsovo market segments, market trends and opportunities, and any further data you may need to thrive in the tibsovo industry. This tibsovo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tibsovo market size has grown strongly in recent years. It will grow from $1.08 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to limited availability of idh1-targeted drugs, growing prevalence of aml and cholangiocarcinoma, reliance on conventional chemotherapy, low awareness of genetic mutation testing, restricted access to specialized oncology clinics.

The tibsovo market size is expected to see strong growth in the next few years. It will grow to $1.7 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to development of novel oral targeted therapies, increasing genetic testing and personalized medicine adoption, expansion of combination treatment regimens, rising investment in oncology research, growth of hospital and specialty clinic networks. Major trends in the forecast period include rising adoption of targeted therapies for aml and cholangiocarcinoma, increasing use of oral targeted drugs over intravenous administration, expansion of combination therapy approaches, growing awareness of idh1 mutation testing, enhanced focus on personalized cancer treatment.

The increasing prevalence of acute myeloid leukemia is expected to propel the growth of the TIBSOVO market going forward. Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow that disrupts normal blood cell production, weakens immune function, and adversely affects overall health. The prevalence of acute myeloid leukemia is rising mainly due to the growing global aging population, as AML predominantly affects older adults, and increased life expectancy results in a larger population reaching the age group most at risk for this disease. TIBSOVO supports the treatment of acute myeloid leukemia by selectively targeting IDH1-mutated cancer cells, inhibiting abnormal cell proliferation, slowing disease progression, improving therapeutic response, and enhancing survival outcomes by helping restore normal blood cell formation. For instance, in February 2023, according to a report published by the Leukemia Foundation, an Australia-based non-profit organization, between 2022 and 2035, more than 7,000 children, 6,000 young adults, and 108,000 adults aged 25-65 are projected to be diagnosed with blood cancers, primarily including ALL, AML, and non-Hodgkin lymphoma. Therefore, the increasing prevalence of acute myeloid leukemia is driving the growth of the TIBSOVO market.

Major companies operating in the TIBSOVO market are concentrating on securing regulatory approvals to expand the drug's market presence and reinforce its leadership in treating IDH1-mutated cancers. Regulatory approvals are formal authorizations granted by health authorities that permit a drug to be marketed and prescribed for specific conditions after verifying its safety and efficacy. For example, in October 2023, Servier Laboratoires, a France-based pharmaceutical company, received approval from the European Commission for TIBSOVO (ivosidenib tablets), making it the first and only IDH1-targeted therapy authorized in Europe for two difficult-to-treat cancers. It is approved for use in combination with azacitidine for newly diagnosed AML patients with an IDH1 R132 mutation who are not eligible for standard induction chemotherapy, and as a monotherapy for adults with locally advanced or metastatic cholangiocarcinoma carrying the same mutation following at least one prior systemic therapy. This approval, supported by orphan drug designation, addresses significant unmet medical needs and offers patients improved treatment options and quality of life.

In December 2023, Servier Group, a France-based pharmaceutical company that markets TIBSOVO (ivosidenib tablets) as a targeted therapy for patients with IDH1-mutated cancers, acquired exclusive rights to develop, manufacture, and commercialize TIBSOVO from CStone Pharmaceuticals for $44 million. This acquisition is intended to strengthen Servier Group's presence in the fast-growing China and Singapore markets by securing exclusive rights to TIBSOVO, expanding its oncology portfolio with a precision therapy for IDH1-mutated cancers, and accelerating patient access to this innovative treatment in these strategic regions. CStone Pharmaceuticals is a China-based biopharmaceutical company focused on oncology drug development.

Major companies operating in the tibsovo market are Servier Laboratoires, Agios Pharmaceuticals

North America was the largest region in the tibsovo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tibsovo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tibsovo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tibsovo market consists of sales of products including oral tablets, extended-release tablets, soft gel capsules, intravenous injection, and subcutaneous injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tibsovo Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses tibsovo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tibsovo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tibsovo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Tablets; Combination Therapy
• 2) By Drug Administration: Oral Administration; Intravenous Administration
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Cancer Treatment; Acute Myeloid Leukemia; Targeted Therapy
• 5) By End User: Hospitals; Specialty Clinics; Research Institutions; Homecare Settings
• Subsegments:
• 1) By Tablets: Oral Tablets; Extended-Release Tablets
• 2) By Combination Therapy: Tibsovo + Chemotherapy Agents; Tibsovo + Targeted Therapy Agents
• Companies Mentioned: Servier Laboratoires; Agios Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.